The role that nutritional factors play in mammalian development has received renewed attention over the past two decades as the scientific literature has exploded with reports that folic acid supplementation in the periconceptional period can protect embryos from a number of highly significant malformations. As is often the case, the relationship between B vitamin supplementation and improved pregnancy outcomes is more complicated than initially perceived, as the interaction between nutritional factors and selected genes must be considered. In this review, we attempt to summarize the complex clinical and experimental literature on nutritional factors, their biological transport mechanisms, and interactions with genetic polymorphisms that impact early embryogenesis. While not exhaustive, our goal was to provide an overview of important gene-nutrient interactions, focusing on folic acid and vitamin B 12 , to serve as a framework for understanding the multiple roles they play in early embryogenesis.
Introduction
There is a substantial body of experimental and epidemiological data demonstrating the importance of the interplay between nutritional and genetic factors in the development of complex congenital malformations. Interacting upon a framework of socioeconomic, temporal, special, and individual (e.g., ethnicity, health) considerations, nutrition must now be considered as an important precipitating factor for the expression of congenital malformations [1] [2] [3] [4] . The importance of the maternal nutritional status for the development of the mammalian embryo has long been appreciated. It was apparent over 50 years ago that the B vitamin folic acid plays a pivotal role in promoting normal embryonic development. There is abundant evidence demonstrating that either excessive or deficient amounts of selected dietary components can adversely affect the developing embryo. For example, experimental animals subjected to conditions of folate deprivation often fail to survive to term, or present with multiple malformations [5, 6] . These include more recent studies using genetically modified mice in which the ability to bind and transport folic acid has been ablated, resulting in embryos bearing what we now consider to be classic "folate-responsive" congenital malformations of the neural, cardiac, and craniofacial systems [7] [8] [9] .
Over the last two decades, there has been growing awareness of the role that nutritional factors, in particular B vitamins, play during embryonic development. With the recognition that maternal periconceptional supplementation with folic acid is effective in reducing the risk of selected human neural crest cell-related congenital malformations, most notably neural tube defects (NTD), there has been a resurgence of interest in trying to understand the underlying biological mechanisms involved in embryonic folate utilization. Clinical trials conducted in several different countries have repeatedly demonstrated that periconceptional supplementation with folic acid can significantly reduce the risk of NTD by as much as 70%. There are also highly suggestive data documenting the protective Richard H. Finnell, Gary M. Shaw, Edward J. Lammer, and Thomas H. Rosenquist effects of folic acid for other congenital abnormalities, such as conotruncal heart defects and craniofacial malformations [10] [11] [12] [13] [14] [15] [16] [17] [18] . These malformations are associated with enormous emotional and health care expenses. For example, the estimated lifetime cost for children born each year in California with spina bifida exceeds $58,375,000 (based on 1988 US dollars). Similarly, those born with a conotruncal heart defect have medical costs exceeding $287 million, and for orofacial clefts, the costs are nearly $86 million [19] . These figures for California can be multiplied 10-fold to arrive at an estimate of the lifetime medical costs for these same malformations among children born annually throughout the United States. Further, when one considers that for NTD, based on 1990 data, the US figures account for only slightly more than 1% of those born worldwide, the annual, global costs of these conditions must approach $50 billion (Stein Emil Vollset, University of Bergen, Norway, personal communication). Clearly, the public health impact of these congenital defects cannot be overstated.
In the course of trying to understand the mechanisms underlying the protective effects of periconceptional folic acid supplementation, investigators have focused their efforts on identifying those genes that interact with critical nutritional factors to regulate key morphogenetic events during embryogenesis. For the most part, the genes that have been interrogated for single nucleotide polymorphisms (SNP) that might be associated with increased risks of adverse pregnancy outcomes are those coding for enzymes in the folate biosynthetic pathway [20] [21] [22] [23] . Genes related to folate binding and transport have also been investigated [24] [25] [26] [27] [28] [29] . Although other genes, including transcription and growth factors and those that regulate cellular housekeeping activities, also represent potential candidate genes for regulating susceptibility to complex birth defects [30] [31] [32] , this review will limit its focus to folate, folate-related genes, and vitamin B 12 , as factors influencing serious structural birth defects.
Gene-nutrient interactions

Folate pathway genes and risk of neural tube defects
Several types of complex congenital malformations, including NTD and conotruncal heart and craniofacial defects, are considered to be folate-responsive. In addition, women who take folic acid-containing multivitamins during the periconceptional period are believed to be at reduced risk for having infants with such congenital anomalies [10, 11, 17, 21, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . While the most common forms of NTD are spina bifida and anencephaly, the clinical spectrum of NTD also includes craniorachischisis and iniencephaly. Due to the complex etiology of NTD, the identification of genes involved in conferring susceptibility to these conditions remains a difficult undertaking [47] [48] [49] [50] [51] . Efforts have been complicated by a number of factors. Notably, if such genes are involved, they could exert their influence through the maternal and/or embryonic genotype, and/or through interactions with other genetic or nongenetic risk factors. Only recently are study designs and analytic strategies to account for these complexities beginning to emerge [52] [53] [54] [55] . Another complicating aspect is the relative rarity of NTD, which makes it difficult to acquire sufficiently large study samples, and hinders replication efforts. To date, not a single gene or genetic variant has emerged as a consistent risk factor for NTD across multiple populations. Moreover, no gene has been sufficiently studied to warrant its exclusion as a possible candidate risk factor gene.
Evidence from the past two decades demonstrating the ability of folic acid to reduce the prevalence of NTD has resulted in mutation and polymorphism screening of genes encoding proteins directly involved in folic acid metabolism, uptake, and transport. Those genes encoding the approximately 30 proteins directly involved in folic acid metabolism and transport have become the target of extensive investigation. Several folate pathway candidate genes that have been interrogated for disease-associated polymorphisms include folate receptor alpha (FRα) and beta (FRβ), reduced folate carrier (RFC), the 5,10-methylene-tetrahydrofolate reductase (MTHFR), cystathionine B synthase (CBS), methionine synthase (MTR), methionine synthase reductase (MTRR), methylenetetrahydrofolate dehydrogenase (MTHFD), and serine hydroxymethyltransferase (SHMT), to name just a few [15, 16, 20-22, 24-26, 28, 56-66] . For a more comprehensive list of candidate genes, the readers are referred to reviews by Blom et al. [49] and Greene and Copp [67] .
Generally speaking, the associations that have been identified between NTD risk and variants of folaterelated genes have been weak and have not been consistently replicated [68] . However, variants of several of the above-mentioned folate genes, including MTHFR, MTR, and MTRR, have been associated with the risk of NTD in one or more studies. Moreover, several studies suggest that the risk of these conditions is indeed influenced by the genotypes of both the mother and the embryo and by gene-environment interactions [28, 68] . The association studies that are currently in progress in multiple institutions from around the world will become increasingly more powerful in their ability to identify true risk factors as the numbers of informative families and isolated samples become available for study. The National Birth Defects Prevention Study in the United States is one source of new biological samples for investigation [69] .
One relatively well-studied, folate-related candidate gene is the human folate receptor alpha (hFRα; FOLR1), which is a GPI-anchored membrane-bound protein with a high affinity for 5-methyl-tetrahydrofolate (5-Me-THF). This receptor, located within the lipid raft of the cell membrane [70] , transports folates across the cellular membrane in the only folate-specific step in folate transport. The folate receptor binds folate and internalizes the bound dietary-or vitamin-derived folate via receptor-mediated endocytosis. There are three isoforms of this receptor (α, β, and γ) in humans and mice (Folbp1, 2, and 4) [71] . The transepithelial (transcellular) transport of folic acid presumably consists of three steps: 1) Folic acid binds to the folate receptors present on the surface of the cell and is internalized into the cell via endocytosis [72] [73] [74] . This step may be mediated by folate receptors, or the reduced folate transporter-1 (RFC1). 2) Folic acid then traverses the cytosol to the basolateral side of the cell (transcytosis). 3) Folic acid is finally pumped out from the basolateral surface of the cell. Although evidence exists for the mechanism of entry of the folic acid, there is little proof of the details of the journey of folic acid through the cell and finally its exit. Thus, there is a significant data gap for the sum total of all three steps, collectively referred to as the transepithelial transport of folic acid. Because placental folate receptors are critical in transporting folates to developing fetuses, any reduction in placental folate receptors and their functionality would predict a net reduction in fetal folate delivery. Should this prediction be extended back in developmental time to the yolk sac endoderm during the period of neural tube closure, it is likely that the neuroepithelial cells would be folate-deprived.
Furthermore, based on the above, it is easy to imagine how a slight conformational change in the folate receptor altering its ability to adequately transport sufficient quantities of folate to the embryo at critical periods of development might make an embryo susceptible to NTD. This is further supported by the high concentration of these receptors in the maternal placenta, as well as the syncytiotrophoblast and fetal neuroepithelium [75] . Because most embryonic cells do not express FOLR1, the presence of these receptors in cells of the developing neural tube suggests a critical role for folic acid during normal neural tube closure [76] . Additional support for this gene's being a strong candidate comes from mouse studies in which the homolog of this gene, folate-binding protein-1 (FolR1), was inactivated by gene targeting, and the nullizygous mice presented with NTD and other folate-dependent congenital defects [7] [8] [9] [77] [78] [79] .
Investigation of this gene in human subjects has focused upon the exons responsible for protein function and the promoter region. Barber and colleagues [24, 25] conducted an exhaustive search for nucleotide polymorphisms within the coding region of FOLR1 utilizing spina bifida cases and matched control samples collected as part of a live-born phenylketonuria screening program in California. The investigations into this gene failed to reveal any polymorphic nucleotides within either the coding region or intronic bases surrounding the intron-exon boundaries of the FOLR1 locus [24] . In a subsequent investigation, Trembath et al. [60] screened the FOLR1 coding region by single strand conformational polymorphism analysis in a sample of 154 NTD cases and their relatives obtained from Midwestern NTD clinics. Only a single case presented with a gene alteration that consisted of a single, silent mutation (TGA→TAA) within the stop codon. This mutation was identified in a male, non-Hispanic Caucasian with a meningomyelocele. Analysis of parental DNA verified paternity and determined that the mutation was a de novo event. A separate population of 326 control individuals composed of newborn infants from Iowa revealed a lone atypical sequence that occurred in a phenotypically normal individual that possessed an amino substitution of serine to asparagine within exon 6 of hFR-α, and thus, no significant association with NTD risk [60] . In addition to studies of the protein-coding region, evaluations of the FOLR1 promoter region have revealed that the nucleotides encompassing a segment of the 5′UTR that have been shown to be necessary for maintenance of normal transcription rates [61] contained three different polymorphisms (631T→C, 610A→G, and 762G→A). These three polymorphic sites formed only two variant alleles, as two of the substitutions (631T→C and 610A→G) were always observed together. No statistically significant association or trend was observed for either a risk or a protective effect for children or mothers with any of the different allelic forms of this gene (p > .05). Although the frequency of the polymorphic alleles showed significant variation between sampling locations, there was no significant association of either allele with NTD risk. These polymorphic promoter alleles appear to represent neutral variation within the promoter region of FOLR1. Therefore, unlike the coding region of this gene, which showed very little variation, the promoter region does not appear to be under the same degree of selective pressure to remain invariant, and the possibility exists that clinically significant SNP exist within these regions that might explain the population burden for NTD [25] . More recently, Nilsson and Borjel [80] identified a 25-bp deletion in the 5′UTR of FOLR1 in three patients with hyperhomocysteinemia. Three other promoter-region mutations in this gene were also observed in individual patients out of a study population of 728, indicating that alterations in the noncoding region of this gene are also quite rare [80] .
A secondary means of folate transport into cells is conferred by the reduced folate carrier gene (RFC1). Not only does RFC1 serve to shuttle folate into cells, but it also regulates the means by which the cell's endocytotic vesicle delivers 5,10-methylene-tetrahydrofolate reductase (MTHFR) to the cytoplasm [81] [82] [83] [84] . This is important, as MTHFR, a suggested risk factor for NTD in its own right [63] (see below), converts 5,10-methylene-tetrahydrofolate to 5-methyl-tetrahydrofolate, providing the single carbon molecules necessary for the remethylation of homocysteine. In an effort to describe the underlying relationship between folic acid intake and spina bifida risk, our group was the first [28] to investigate gene variants in infants for a coding region SNP of RFC [84] . Higher plasma folate levels have been observed in A80/A80 individuals than in G80/G80 [84] . We investigated whether spina bifida risk was influenced by an interaction between RFC1 and maternal periconceptional use of vitamins containing folic acid. The percentages of case infants with the A80/A80, G80/G80, and G80/A80 genotypes were 27.2, 28.0, and 44.7, respectively. The percentages of control infants were similar (26.1, 29.3, and 44.7). Odds ratios of 1.0 (95% CI, 0.5 to 2.0) for the G80/G80 genotype and 1.1 (95% CI, 0.6 to 2.0) for the G80/A80 genotype were observed relative to the A80/A80 genotype. Among mothers who did not use vitamins, spina bifida risk was 2.4 (95% CI, 0.8 to 6.9) for infants with genotype G80/G80 compared with those with A80/ A80 genotype. Among mothers who did use vitamins, the risk was 0.5 (95% CI, 0.1 to 3.1) for infants with the G80/G80 genotype. Thus, this study revealed modest evidence for a gene-nutrient interaction between infant RFC1 G80/G80 genotype and maternal periconceptional intake of vitamins containing folic acid, on the risk of spina bifida. More recently, we have identified similar evidence for a gene-nutrient interaction between infant homozygosity for RFC1 G80, maternal vitamin use, and risk of neural crest cell-derived heart defects (conotruncal defects) [85] . Specifically, the authors observed an approximate 1.6-fold and 2.3-fold increased risk of conotruncal defects associated with the homozygous 80GG and heterozygous genotypes, respectively. However, an elevated risk of cleft lip and palate or cleft palate was not observed. When the additional variable of periconceptional use of vitamins containing folic acid was analyzed, again, only infants with conotruncal defects showed an association with the homozygous mutant genotype (80G) [85] .
There have now been several other groups who have also investigated the RFC1 A80G polymorphism for an association with NTD risk. Pei and co-workers [86] [87] [88] in China compared allelic frequencies between populations from the north and south of the country. There were significant differences between these two populations with respect to the prevalence of the GG genotype, with 32% of northerners being homozygous, while only 23% of study individuals from southern China were GG homozygotes. As the rate of NTD is significantly higher in the north, the increased prevalence of the high-risk genotype was consistent with this observation [87, 88] . Furthermore, based upon the analysis of the RFC1 genotypes, the G allele frequency among infants with NTD (64.4%) was significantly higher than that of the control infants (52.5%). Infants with the GG genotype were at a 2.56-fold increased risk of an NTD compared with infants with the AA genotype, and this risk increased to 7.7-fold when the mothers did not receive folate supplementation [88] . A comparable NTD risk was similarly observed in an Italian spina bifida population for the RFC1 A80G polymorphism [27] . A study in Montreal revealed that the RFC1 A80G polymorphism was an NTD risk factor when the mothers' red blood cell folate concentrations were low. This combination resulted in a highly significant 4.6-fold increased NTD risk [89] . More recently, Vieira and colleagues [90] examined this same polymorphism and failed to find an association either with NTD, or with craniofacial defects. Using a pedigree disequilibrium test [91] on 388 NTD-affected families, there was no evidence of transmission distortion with the RFC1 A80G polymorphism and NTD risk [90] .
An important component of the folic acid metabolic pathway is the amino acid homocysteine; even mildly elevated levels of maternal homocysteine are often associated with an increased risk of an NTD-affected pregnancy [92] [93] [94] . Homocysteine itself has a dual role in the folate pathway: 1) it is the precursor of methionine via the remethylation pathway; and 2) it is the precursor of cystathionine via the transsulfuration pathway. S-adenosyl methionine, acting as a regulator between remethylation and transsulfuration, is an activator of CBS-mediated homocysteine transsulfuration and an inhibitor of MTHFR thereby inhibiting remethylation [95] . Thus, MTHFR serves as one of the cell's principal means of regulating intracellular concentrations of methionine and homocysteine. MTHFR is the rate-limiting step in homocysteine remethylation, and thus mutations in this gene can lead to elevations in homocysteine concentrations. The gene that codes for the MTHFR enzyme is the one gene that has been most often described as a potential risk factor for NTD. The MTHFR gene, composed of 11 exons with known alternative splicing, has been mapped to the short arm of chromosome 1 (1p36.3) and produces a protein product that is approximately 77 kDa.
One well-documented variant in the MTHFR gene (677C→T) has been described and is associated with reduced enzymatic activity that has been linked to increased plasma homocysteine levels in homozygous (TT) individuals if their folate intake is low [62, 96] . This occurs in the homozygous state in 10% to 25% of the population and results in a thermolabile form of the enzyme associated with 50% to 60% reduced enzyme activity [63] . Over the last several years, multiple research groups have reported a threefold to sevenfold increased NTD risk of homozygosity for this MTHFR mutation in Holland and Ireland [62] examined this common MTHFR polymorphism in a population-based case-control set of samples that included over 200 cases of spina bifida. In addition to the genotype information, data were collected on maternal vitamin consumption during the periconceptional period. When the homozygous 677T/677T variant genotype was observed in an infant whose mother took multivitamins, there was only a modest tendency toward an increased odds ratio (OR = 1.2; 95% CI, 0.4 to 4.0) relative to the reference group, who were infants with the homozygous 677C/677C genotype whose mothers took multivitamins. For cases in which the mother did not take multivitamins and the infant had the 677TT genotype, there was a slightly higher odds ratio (OR = 1.6; 95% CI, 0.8 to 3.1). These results are consistent with a small interaction between genotype and maternal vitamin use, as the risk of NTD appears higher among the offspring of women who did not take folic acid, but the difference between the two risk estimates was not substantial nor was the difference statistically significant. Therefore, this interaction does not appear to have a major biological impact on NTD risk. Studies focusing on maternal rather than infant MTHFR genotype have suggested that folate deficiency and/or the TT maternal genotype are important risk factors for NTD [65, 66] . A study by Shields and coworkers [98] identified an NTD risk of the MTHFR TT genotype in the offspring, but not in the mothers. Since the genotype leads to higher homocysteine levels only if the folate status is low, it is highly unlikely that it is a significant factor contributing to the overall population burden of NTD risk.
Botto and Yang [63] performed a meta-analysis on MTHFR data from a number of different countries and ethnic groups with regard to the frequency of the C677T allele. They reported a pooled odds ratio of 1.7 for NTD risk among infants with the 677T/677T homozygous genotype, with a slightly lower odds ratio for infants who were heterozygous for the variant C677T allele, suggesting a relationship between the number of variant 677T alleles and risk of NTD. Furthermore, they developed a pooled attributable risk of 6% for infants who were homozygous for the variant 677T allele. This calculation assumes that there is a causal relationship between the MTHFR gene and the development of NTD, and that the gene exerts an independent effect on risk. With regard to homozygosity for the MTHFR 677T variant allele, it appears that it is only associated with an increased risk of spina bifida in some populations, and only in certain studies within those populations.
Methionine synthase, also known as 5-methyl-tetrahydrofolate homocysteine methyltransferase (MTR), catalyzes the remethylation of homocysteine to methionine with the cofactor methylcobalamin acting as an intermediate methyl carrier. MTR plays a critical role in maintaining adequate intracellular methionine levels, as well as regulating the folate pool. Severe deficiency of MTR activity leads to megaloblastic anemia, homocysteinuria, and hyperhomocysteinemia. The human MTR gene has been cloned and mapped to chromosome 1q43. A polymorphism of MTR gene (A2756G), which changes the 919th amino acid from Asp to Gly, has been widely found in the general population [99] . This polymorphism does not seem to change plasma folate, vitamin B 12 , or homocysteine concentrations [52] [53] [54] . Moreover, several studies have found no association between embryonic genotype for this variant and the risk of spina bifida [39, 57, 100] . However, Doolin and colleagues [101] found evidence of an association between maternal genotype for this variant and the risk of spina bifida in the offspring. A recent study demonstrated that individuals with the GG genotype tend to have slightly lower tHCY concentrations [102] . In terms of enzyme function, the cobalamin cofactor of MTR becomes oxidized over time and the enzyme becomes inactivated. Regeneration of the functional enzyme requires reductive methylation catalyzed by methionine synthase reductase (MTRR). Phenotypic expression of MTRR deficiency is considered to be similar to those patients with cblE [103] . The MTRR gene has been localized to chromosome 5p15.2-15.3 [104] . A common polymorphism of this gene (A66G), which changes the 22nd amino acid from isoleucine (Ile) to methionine (Met), has been found to be associated with increased NTD risk either when the cobalamin status is low, or when the MTHFR 677TT genotype is present in an infant [105] . Moreover, an association between maternal genotype for this variant and spina bifida risk has also been reported [101] . This is true despite the fact that this polymorphism alone does not change the patient's homocysteine levels. This association has also been reported in Polish subjects with NTD [106] . The G allele at this locus has also been associated with an increased risk of Down syndrome when it occurs in combination with the MTHFR 677CT or TT genotypes [107, 108] . Those individuals with the AA genotype have higher levels of tHCY and a 4% increase of cardiovascular disease risk [109] .
More recently it was determined that infants with the MTRR AG genotype had a 3-fold higher risk of NTD when compared with the AA genotype (OR = 2.98; 95% CI, 1.26 to 7.05; p < .05) [23] . Infants with the MTR AG genotype also had a 2.7-fold higher risk of NTD compared with the AA genotype (OR = 2.65; 95% CI, 1.12 to 6.26; p < .05). It is noteworthy that infants who are heterozygotes for both MTRR and MTR (AG + AG) had exceptionally elevated NTD risks, with odds ratios of 14.7 compared with wild type (AA + AA) (OR = 14. 7; 95% CI, 3.2 to 67.5) [23] . A comparable result was observed in the mothers of NTD cases (OR = 9.1; 95% CI, 1.9 to 43.1). These results indicated that the MTRR and MTR genes interact to increase the infant's NTD risks [23] .
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Folate and vitamin B 12 during development Volcik and colleagues [29] investigated whether SNP within the enzyme thymidylate synthase (TS) contributed to spina bifida risk. Genomic DNA was extracted from newborn-screening blood spots obtained from 264 case infants with spina bifida and 259 nonmalformed control infants [29] . Genotype frequencies of two polymorphisms in the TS gene-a 28-bp tandem repeat in the promoter enhancer region (TSER) and a 6-bp deletion in the 3′UTR-were determined by PCR and RFLP methods. These polymorphisms are known to influence levels of expression of the TS enzyme, which may affect plasma folate levels and, indirectly, plasma homocysteine concentrations. Additionally, all seven exons of the TS gene were sequenced to identify variations within the coding region of the gene. We found that the TSER 2/2 homozygous genotype was associated with a slightly increased risk of spina bifida infants (OR = 1.4; 95% CI, 0.8 to 2.4). When the cases and controls were divided into separate ethnic groups, this risk increased by 4-fold with the TSER 2/2 homozygous genotype (OR = 4.0, 95% CI, 1.8 to 8.8), and by 3-fold with the 3′UTR-/-homozygous genotype (OR = 3.6; 95% CI, 1.3 to 10.1) in non-Hispanic white cases. The combined TSER 3′UTR (2/2,-/-) haplotype showed a more than 4-fold increased risk of spina bifida within this specific ethnic group (OR = 4.7, 95% CI, 1.1 to 19.8). This study is the first to evaluate whether TS polymorphisms contribute to the risk of spina bifida. The current findings indicate that polymorphisms in the untranslated regions of the TS gene are associated with 4-fold or greater increased risks of spina bifida in non-Hispanic whites.
Folate pathway polymorphisms and non-NTD complex birth defects
The association between folate supplementation and birth defects extends beyond NTD to heart defects as well. Shaw and co-workers [38] were the first to observe a 30% risk reduction for conotruncal defects among the offspring of women who used multivitamins containing folic acid in early pregnancy. These findings were subsequently confirmed by several other investigators [110, 111] , although a very small study by Bower and Stanley [112] failed to obtain this same association. Several studies have explored a potential role between the polymorphisms of the MTHFR gene and risk of conotruncal heart defects. Storti and colleagues [113] examined 103 children with conotruncal heart defects and did not observe an excess of mutant genotypes (677T) among the affected children or in their mothers. They did report a combined odds ratio for the two polymorphisms (677T and 1298C) of 2.31 (95% CI, 0.49-10.82), although this was not statistically significant [113] . In an effort to better understand multiple genetic risk factors in the etiology of conotruncal heart defects, Shaw and co-workers [114] examined gene-only and gene-environment interactions involving 32 SNP found in genes involved in homocysteine metabolism, coagulation, cell-cell interactions, inflammation, and blood pressure regulation. Of the 32 SNP investigated, 4 were found to have odds ratios greater than 2.0, while 2 were protective, with odds ratios less than 0.5 [114] . The genes that appeared to be risk factors included prothrombin, F7 promoter, platelet glycoprotein IIIa, and atrial natriuretic precursor peptide, none of which were considered to be involved with folate-homocysteine metabolic pathways. Interestingly, the two genes associated with reduced risks are tumor necrosis factor G and ADD1. With respect to potential gene-environment interactions involving maternal folate supplementation and MTHFR genotypes, there was no evidence of an association between the MTHFR 677 CT or TT genotype and increased risk of conotruncal heart defects [114] .
Our laboratory [15, 39, 86] and others [115, 116] have investigated the role that specific genes associated with folate transport and metabolism may contribute to orofacial clefting risk. Results have been equivocal for the most studied gene, MTHFR. Mills and colleagues [116] observed an increased risk of clefting among individuals who were homozygous for the 677 C to T transition. However, other investigators [5, 39, 115] did not observe an association, alone or in combination with low maternal folic acid intake. We failed to observe an association with the homozygous genotype and clefts, although we did observe an association with spina bifida [28] . We have observed evidence of a gene-nutrient interaction in the risk of clefting in a study that investigated maternal supplemental folic acid intake and infant transforming growth factor-alpha genotypes [64] .
Vitamin B 12 and risk of complex birth defects
Several nutritional factors other than folic acid have also been suggested as modifying factors for complex birth defects. It is known that methylation of DNA can be influenced by the dietary contributions of methyl donors such as choline, vitamin B 12 , and methionine. These nutrients are highly interrelated in methyl group metabolism, and an alteration in one affects the others [117] . One factor in particular that has been implicated in NTD risk is vitamin B 12 [118] This may be a result of intracellular vitamin B 12 acting as a cofactor in the remethylation of homocysteine to methionine in a reaction catalyzed by the enzyme methionine synthase [119] . Vitamin B 12 is required as a cofactor for the remethylation of homocysteine to methionine, a reaction that is catalyzed by the action of methionine synthase (MTR). Dietary vitamin B 12 is bound to gastric intrinsic factor (IF), and absorbed in the ileum by cubulin (CUB) and amnionless (AMN). In plasma, approximately 20% of vitamin B 12 is bound to transco- balamin. Vitamin B 12 is released from transcobalamin in the lysosome and is oxidized to cobalamin in the cytosol. Via the action of several steps (e.g., MMAHC, MTRR) methylcobalamin is formed, which is the cofactor of methionine synthase.
Plasma homocysteine is elevated in patients with vitamin B 12 deficiency owing to impairment in the conversion of homocysteine to methionine, and elevated homocysteine has been implicated in risk of conotruncal heart defects [93, 120, 121] . Lower levels of plasma vitamin B 12 , independent of folate, have been associated with increased risks of several congenital malformations [122] [123] [124] [125] [126] .
Several studies show no differences between serum levels of vitamin B 12 or folate in NTD case versus control mothers [127] [128] [129] , while other studies show lower maternal serum vitamin B 12 levels in NTD cases [122, [130] [131] [132] . In a recent comprehensive review, Ray and Blom [126] critiqued and synthesized the evidence from 17 epidemiologic studies that investigated the association between vitamin B 12 and NTD risk, and concluded that evidence did indeed exist for a moderate risk between vitamin B 12 insufficiency and NTD risk. Other studies also indicate that vitamin B 12 concentrations appear modified internally across the placenta, where a lower vitamin B 12 status may or may not be present in serum but is significantly lower in the amniotic fluid of NTD case versus control mothers [133] [134] [135] [136] [137] . Additionally, Afman [138] studied five SNP in the coding region of the transcobalamin II (TCN2) gene, but none were associated with a significantly increased risk of NTD. Three of the TCN2 SNP affected the transcobalamin concentration, but these variants only partially accounted for the reduced proportion of vitamin B 12 binding observed [138] . A populationbased, case-control study conducted in a Hispanic population along the Texas-Mexico border identified a three-old increase in the NTD risk among the offspring of mothers who were in the lowest vitamin B 12 quintile relative to those mothers in the highest quintile [139] . With respect to specific genetic polymorphisms, a study by Swanson and colleagues [140] failed to find any increased NTD risk associated with any of six transcobalamin II SNP.
Extending the vitamin B 12 hypothesis, studies have also focused on folate-and vitamin B 12 -related genes such as methionine synthase (MTR) and MTR reductase (MTRR). These studies indicate that MTRR-dependent reduction of vitamin B 12 may increase the risk of spina bifida [141, 142] . Furthermore, studies on folate and vitamin B 12 enzymes have expanded to include gene-gene interactions or epistasis between MTHFR 677C→T, MTHFR 1298 A→C, MTRR 66A→G, serine hydroxymethyltransferase (SHMT 1420C→T), cystathionine beta-synthase (CBS 844ins68), glutamate carboxypeptidase II (GCPII 1561C→T), and RFC 80G→A [40, 89, 142] . Collectively, the genes involved in folate biochemistry and their respective polymorphisms appear to only produce small risk increases. This has introduced the idea that cumulative environmental conditions act on individuals with specific genetic predispositions, leading to threshold infringement, after which an NTD is produced [143, 144] .
Lowered levels of dietary vitamin B 12 have not been adequately investigated as a risk factor for other folateresponsive birth defects, such as conotruncal heart defects. That is, we are aware of a very limited number of small studies that investigated whether low senim vitamin B 12 concentrations in mothers were associated with risk of infants having congenital defects [125] .
Conclusion and public health implications
The risk reduction for NTD, clefts, or conotruncal heart defects is unlikely to be explained by a simple maternal vitamin deficiency, or by a simple maternal absorption deficiency [122, 133, 134, [145] [146] [147] [148] [149] [150] . Evidence points toward disordered folate metabolism in some individuals with malformations, with the metabolic error affecting uptake, transport, and/or metabolism of folate by fetal cells [151] . Thus, the epidemiologic and clinical evidence suggests that genetic variation in fetal or possibly maternal folate metabolism may underlie some of the risk reduction associated with maternal folate supplementation. Such genetic variation could explain why the literature is replete with varying risk reductions among population subgroups that took folic acid vitamin supplements, or obtained clinically adequate amounts of folate from their diets [38] .
We believe that multiple genes with small effects, each of which themselves can be regulated by nutritional factors, interact in a combinatorial fashion to create a larger, more significant developmental disequilibrium beyond that which they could have produced individually. Thus, it is the sum total of all of these interacting elements, both genetic and environmental, that leads to the abnormal phenotypes observed in infants with congenital malformations. Currently, research activities include developing new analytic tools to fully exploit gene-nutrient and genegene interactions. It is clear that these approaches to understanding complex trait analyses are necessary in order to synthesize the disparate clues that currently exist regarding the etiology of these malformations. Employment of more specialized techniques, including multiplex and whole genomic approaches for the rapid analysis of multiple genes, will be of utmost importance for investigators in coming years. It is only when we have a better understanding of the mechanisms triggering abnormal developmental pathways that we can dissect out the contribution of nutrientgene interactions and devise effective intervention strategies. Clearly, determining what role nutrition S93 Folate and vitamin B 12 during development plays in development is a major goal. Understanding how specific nutritional factors interact with different genotypes may yield critical clues that will ultimately yield new approaches to prevent preventable birth defects.
